Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Labcorp will acquire BioReference Health assets from OPKO for $722 million plus earnout.

What the company is saying

Labcorp (NYSE:LH) is announcing a binding agreement to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health (NASDAQ:OPK), for $722 million in cash at closing, with a potential additional $150 million earnout tied to 4Kscore Test revenue. The company frames the deal as an expansion of its clinical, women’s health, urology, and corrections testing capabilities, emphasizing broader access to specialty diagnostics and the FDA-approved 4Kscore Test. Labcorp highlights its national scale, network of over 80 additional patient service centers to be acquired, and its support for more than 85% of new FDA-approved drugs and therapies in 2025. Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp, claims the acquisition will deliver affordable, high-quality, specialized diagnostic services and improve patient care. OPKO’s CEO, Phillip Frost, positions the sale as a move to streamline operations and focus on the biopharmaceutical segment, while also expanding access to the 4Kscore Test via Labcorp’s reach. The announcement is confident in tone, focusing on the strategic fit and anticipated benefits, but does not provide historical financials for the acquired business. Both companies will continue to operate independently until closing, with no immediate operational changes.

What the data suggests

The transaction involves a $722 million upfront cash payment, subject to adjustment based on closing business revenues, and up to $150 million in additional earnout contingent on 4Kscore Test revenue. Labcorp expects approximately $250 million in business revenue from the acquired assets in the first year post-close, but the release does not disclose historical revenue, profitability, or margin data for these assets, making it impossible to assess the deal’s accretion or dilution. The operational scope includes over 80 additional patient service centers and the proprietary, FDA-approved 4Kscore Test for prostate cancer risk assessment. Labcorp’s scale is underscored by nearly 71,000 employees, support for more than 85% of new FDA drug approvals in 2025, and over 750 million tests performed globally. The only quantified forward-looking benefit is the $250 million revenue forecast, with no disclosure of expected margins, cash flow, or integration costs. The announcement is detailed on transaction structure and strategic rationale but lacks transparency on the acquired business’s historical performance or expected profitability.

Analysis

The announcement is positive in tone, highlighting a major acquisition and projecting benefits such as strengthened diagnostic capabilities and broadened access to innovative tests. However, the majority of the measurable progress is limited to the signing of an acquisition agreement and disclosure of transaction terms. The most concrete forward-looking claim is the expectation of $250 million in first-year revenue post-close, but there is no historical revenue or profitability data for the acquired assets, nor any pro forma financials. The transaction is subject to regulatory approvals and closing conditions, so benefits are not immediate but likely within a 6-24 month window. The capital outlay is substantial ($722 million upfront plus up to $150 million earnout), yet the only quantified benefit is a revenue forecast, with no disclosure of expected profitability, margins, or cash flow. The narrative is inflated by broad claims about strengthening capabilities and access, which are not substantiated by operational or financial evidence in the release.

Risk flags

• ●Regulatory approval risk is present, as the transaction cannot close until all required regulatory and customary conditions are satisfied. Delays or failure to obtain approvals could postpone or jeopardize the deal, affecting both companies’ strategic plans.
• ●Financial transparency risk is significant, since the announcement omits historical revenue, EBITDA, or margin data for the acquired assets. This limits investors’ ability to assess whether the $722 million upfront price and $150 million earnout are justified by the business’s earnings power.
• ●Integration risk exists, as Labcorp will need to absorb over 80 new patient service centers and integrate BioReference Health’s operations, including the proprietary 4Kscore Test. Operational disruption, cultural differences, or unforeseen costs could erode anticipated benefits.
• ●Earnout risk is tied to the $150 million contingent payment based on 4Kscore Test revenue. If adoption or reimbursement for the test underperforms, the total consideration may be lower, but anticipated revenue synergies could also fall short.
• ●Strategic focus risk for OPKO arises from divesting a major diagnostics business to focus on biopharmaceuticals. If OPKO fails to execute in its core segment, the sale may not deliver intended shareholder value.

Bottom line

Labcorp’s $722 million acquisition of BioReference Health assets from OPKO, with a possible $150 million earnout, is a major bet on expanding specialty diagnostics and proprietary testing. The only quantified benefit is an expected $250 million in first-year revenue, but the absence of historical financials or margin data for the acquired business makes it impossible to judge the deal’s value creation potential. Regulatory and integration risks are material, and the earnout structure means part of the purchase price is contingent on future 4Kscore Test performance. For OPKO, the deal provides cash and a sharper focus on biopharma, but success depends on execution post-divestiture. Investors should watch for regulatory clearance, closing timing, and future disclosures on profitability and integration outcomes. The most important takeaway is that while the transaction is strategically significant and capital intensive, its financial merits remain opaque until more data is provided.

Announcement summary

(NYSE:LH) Labcorp and (NASDAQ:OPK) OPKO Health, Inc. announced that Labcorp has entered into an agreement to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health. Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections, and certain operational assets, including over 80 additional patient service centers. The acquisition also includes BioReference Health's proprietary 4Kscore® Test, an FDA-approved blood test for predicting the likelihood of aggressive prostate cancer before a biopsy decision. The purchase price for the transaction is $722 million in cash at closing, subject to adjustment based on closing business revenues, and up to an additional $150 million in an earnout based on revenue from the 4Kscore Test. Labcorp expects the business revenue to be approximately $250 million in the first year after close, based on current post-closing forecasts. The transaction is subject to regulatory approvals and customary closing conditions. Until closing, both companies will continue to operate independently with no changes to operations or services. Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp, stated that the acquisition will strengthen Labcorp's ability to deliver affordable, high-quality, specialized diagnostic services and broaden access to innovative diagnostics such as the 4Kscore Test. Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO, stated that the transaction will allow OPKO to streamline operations and focus resources on its biopharmaceutical business, and that Labcorp's national scale will broaden access to the 4Kscore Test. Lazard is serving as Labcorp's financial advisor, Hogan Lovells Cadwalader US LLP as lead transaction counsel, and Parker Poe as real estate counsel. Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, and Greenberg Traurig P.A. as legal counsel. Labcorp has nearly 71,000 employees and provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025. Labcorp performed more than 750 million tests for patients around the world.

Disagree with this article?